Vor Biopharma Inc.
VOR
$1.06
$0.1719.10%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 10.51% | -10.95% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 6.32% | 9.81% | |||
| Operating Income | -6.32% | -9.81% | |||
| Income Before Tax | -5.78% | -11.44% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -5.78% | -11.44% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -5.78% | -11.44% | |||
| EBIT | -6.32% | -9.81% | |||
| EBITDA | -6.63% | -10.06% | |||
| EPS Basic | 40.65% | -8.97% | |||
| Normalized Basic EPS | 40.64% | -8.94% | |||
| EPS Diluted | 40.65% | -8.97% | |||
| Normalized Diluted EPS | 40.64% | -8.94% | |||
| Average Basic Shares Outstanding | 78.26% | 2.28% | |||
| Average Diluted Shares Outstanding | 78.26% | 2.28% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||